Erlotinib News and Research

RSS
Erlotinib is a drug used to treat certain types of non-small cell lung cancer. It is also used together with gemcitabine to treat pancreatic cancer and is being studied in the treatment of other types of cancer. Erlotinib is a type of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor. Also called CP-358,774, erlotinib hydrochloride, OSI-774, and Tarceva.
Pemetrexed plus erlotinib shows benefits in NSCLC

Pemetrexed plus erlotinib shows benefits in NSCLC

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Clovis Oncology reports net loss of $30.7 million for first quarter 2014

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

AVEO joins with Biodesix to develop and commercialize ficlatuzumab for treatment of NSCLC

New era of lung cancer therapy close to dawning

New era of lung cancer therapy close to dawning

Cell-free DNA analysis allows noninvasive tumour genotype monitoring

Cell-free DNA analysis allows noninvasive tumour genotype monitoring

NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

Erlotinib has promising potential to improve treatment for cervical cancer

Erlotinib has promising potential to improve treatment for cervical cancer

Lung cancer patients with Del19 mutation benefit most from afatinib

Lung cancer patients with Del19 mutation benefit most from afatinib

IGF1R linked to mutation-negative lung cancer erlotinib resistance

IGF1R linked to mutation-negative lung cancer erlotinib resistance

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Everolimus fails to boost advanced NSCLC response

Everolimus fails to boost advanced NSCLC response

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Top-line results from two Phase 3 studies of dacomitinib for patients with advanced NSCLC published

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Neuro-Oncology publishes promising phase 2 results from Agenus’ brain cancer vaccine study

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

Erlotinib ‘dose-to-rash’ strategy effective in advanced NSCLC

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Johns Hopkins researchers use lung cancer drug to shrink chordoma in mice

Novel multi-kinase inhibitor shows early promise in NSCLC

Novel multi-kinase inhibitor shows early promise in NSCLC

Investigational c-Met inhibitor shows early promise in NSCLC

Investigational c-Met inhibitor shows early promise in NSCLC

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy

Toxicity limits benefits of bevacizumab–erlotinib NSCLC maintenance therapy